ArticleActa pharmaceutica Sinica. B2025
Gut microbiota-derived tryptophan metabolites regulated by Wuji Wan to attenuate colitis through AhR signaling activation.
Article in Acta pharmaceutica Sinica. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- The Gut Microbiota-Metabolite-Host Axis in Cardiometabolic Diseases: Bridging Bench to Bedside.Cardiovascular drugs and therapy · 2026Review
- Amino Acid Metabolism in Health and Disease.MedComm · 2026Review
- Article
- Conjunctival Sac-Derived Lactobacillus mucosae MM-1 Metabolite Indole-3-Lactic Acid Attenuates Lens-Induced Myopia in Mice via AHR Activation and TGF-β/Smad Inhibition.Microbial biotechnology · 2026Article
- Formic acid released by intratumoralActa pharmaceutica Sinica. B · 2026Article
- Article
- Indoleacrylic acid mitigates vascular rarefaction and enhances ischemia-induced neovascularization in aging via APLNR signaling.Acta pharmacologica Sinica · 2026Article
- The Gut-Pancreas Axis in Type 1 Diabetes: Emerging Insights into Microbiota and Immune Interactions.International journal of molecular sciences · 2026Review
- Astragaloside IV Alleviates DSS-Induced Ulcerative Colitis by Modulating Host-Gut Tryptophan Metabolism.Foods (Basel, Switzerland) · 2026Article
- Daikenchuto ameliorates dextran sulfate sodium-induced acute and chronic ulcerative colitis by regulating gut microbiota-derived indoles to activate AhR signaling.Chinese medicine · 2026Article
- Mechanisms and therapeutic potential of traditional Chinese medicine for inflammatory bowel disease.World journal of gastroenterology · 2026Review
- Spermine Ameliorates DSS-Induced Ulcerative Colitis in Mice by Improving Mitophagy and Intestinal Microbiota.Life (Basel, Switzerland) · 2026Article
- Fermented Lacticaseibacillus Paracasei Cultures Ameliorate Colitis by Modulating Microbiota-Derived Tryptophan Metabolism and Macrophage Polarization.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Nighttime-restricted feeding disrupts spermatogenesis in mice via gut microbiota-derived KYNA homeostasis.Communications biology · 2026Article
- Gut microbiota in Henoch-Schönlein purpura: from pathogenesis to therapeutic strategies.Frontiers in immunology · 2026Review
- Gut microbiota metabolites in inflammatory bowel disease: advances in mechanistic insights.Frontiers in immunology · 2026Review
- Berberine protects against hypoxia-induced intestinal injury through modulation of gut microbiota and bile acid metabolism.Frontiers in immunology · 2026Article
- Metabolomics Reveals Metabolic Characteristics of Functional Cure in Chronic Hepatitis B Treated With Entecavir Combined With Pegylated Interferon Alpha.BioMed research international · 2026Article
- Gut-microbiota-mediated host immune modulation: mechanisms, pathological dysbiosis, and therapeutic frontiers.Frontiers in cellular and infection microbiology · 2026Review
- The Role of Lactiplantibacillus plantarum CGMCC9513 in Alleviating Colitis by Synergistic Enhancement of the Intestinal Barrier Through Modulating Gut Microbiota and Activating the Aryl Hydrocarbon Receptor.Probiotics and antimicrobial proteins · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Disruption of the intestinal mucosal barrier caused by gut dysbiosis and metabolic imbalance is the underlying pathology of inflammatory bowel disease (IBD). Traditional Chinese medicine Wuji Wan (WJW) is commonly used to treat digestive system disorders and showed therapeutic potential for IBD. In this interdisciplinary study, we aim to investigate the pharmacological effects of WJW against experimental colitis by combining functional metabolomics and gut-microbiota sequencing techniques. Treatment with WJW altered the profile of the intestinal microbiota and notably increased the abundance of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.